PH12013500121A1 - Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response - Google Patents
Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory responseInfo
- Publication number
- PH12013500121A1 PH12013500121A1 PH1/2013/500121A PH12013500121A PH12013500121A1 PH 12013500121 A1 PH12013500121 A1 PH 12013500121A1 PH 12013500121 A PH12013500121 A PH 12013500121A PH 12013500121 A1 PH12013500121 A1 PH 12013500121A1
- Authority
- PH
- Philippines
- Prior art keywords
- inflammatory response
- compounds act
- acid
- general anti
- prostaglandin receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000015433 Prostaglandin Receptors Human genes 0.000 title 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 title 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 108050008995 Prostaglandin F receptors Proteins 0.000 abstract 1
- 101150058615 Ptger1 gene Proteins 0.000 abstract 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 1
- 108090000300 Thromboxane Receptors Proteins 0.000 abstract 1
- 108090001097 Transcription Factor DP1 Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- -1 hydrocarbyl sulfonamide Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075510P | 2010-07-01 | 2010-07-01 | |
| PCT/US2011/042729 WO2012003414A1 (en) | 2010-07-01 | 2011-07-01 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013500121A1 true PH12013500121A1 (en) | 2013-03-11 |
Family
ID=44514984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/500121A PH12013500121A1 (en) | 2010-07-01 | 2011-07-01 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8492424B2 (enExample) |
| EP (1) | EP2588459B1 (enExample) |
| JP (1) | JP5922116B2 (enExample) |
| KR (1) | KR20130141434A (enExample) |
| CN (1) | CN103038219B (enExample) |
| AR (1) | AR082073A1 (enExample) |
| AU (1) | AU2011272716B2 (enExample) |
| BR (1) | BR112013000065A2 (enExample) |
| CA (1) | CA2804194C (enExample) |
| CL (1) | CL2013000002A1 (enExample) |
| CO (1) | CO6680625A2 (enExample) |
| ES (1) | ES2625355T3 (enExample) |
| MX (1) | MX2013000170A (enExample) |
| PH (1) | PH12013500121A1 (enExample) |
| RU (1) | RU2013102967A (enExample) |
| SG (1) | SG186886A1 (enExample) |
| TW (1) | TW201206891A (enExample) |
| WO (1) | WO2012003414A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8859606B2 (en) | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| AU2012358983B2 (en) * | 2011-12-21 | 2017-09-14 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9035071B2 (en) * | 2011-12-27 | 2015-05-19 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| AU2012362579B2 (en) | 2011-12-27 | 2017-08-31 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9845465B2 (en) | 2012-08-15 | 2017-12-19 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| ES2711356T3 (es) * | 2013-01-21 | 2019-05-03 | Allergan Inc | Acción de compuestos en múltiples receptores de prostaglandina proporcionando una respuesta antinflamatoria general |
| AU2014342010B2 (en) * | 2013-10-31 | 2018-12-20 | Allergan, Inc. | 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1H-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof |
| CN106146400A (zh) * | 2015-03-20 | 2016-11-23 | 四川大学 | 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途 |
| US10462745B2 (en) | 2016-01-15 | 2019-10-29 | Google Llc | Systems and methods for extending battery life by monitoring device activity |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| JP2006528938A (ja) * | 2003-05-20 | 2006-12-28 | メルク フロスト カナダ リミテツド | フルオロ−メタンスルホニル置換シクロアルカノインドール、およびプロスタグランジンｄ２アンタゴニストとしてのこれらの使用 |
| ES2298832T3 (es) * | 2003-10-24 | 2008-05-16 | Glaxo Group Limited | Compuestos heterociclicos. |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
-
2011
- 2011-06-28 US US13/170,467 patent/US8492424B2/en active Active
- 2011-07-01 WO PCT/US2011/042729 patent/WO2012003414A1/en not_active Ceased
- 2011-07-01 TW TW100123408A patent/TW201206891A/zh unknown
- 2011-07-01 CN CN201180038338.0A patent/CN103038219B/zh not_active Expired - Fee Related
- 2011-07-01 CA CA2804194A patent/CA2804194C/en active Active
- 2011-07-01 KR KR1020137002639A patent/KR20130141434A/ko not_active Withdrawn
- 2011-07-01 AR ARP110102369A patent/AR082073A1/es unknown
- 2011-07-01 ES ES11734222.0T patent/ES2625355T3/es active Active
- 2011-07-01 RU RU2013102967/04A patent/RU2013102967A/ru not_active Application Discontinuation
- 2011-07-01 JP JP2013518748A patent/JP5922116B2/ja active Active
- 2011-07-01 AU AU2011272716A patent/AU2011272716B2/en not_active Ceased
- 2011-07-01 PH PH1/2013/500121A patent/PH12013500121A1/en unknown
- 2011-07-01 EP EP11734222.0A patent/EP2588459B1/en active Active
- 2011-07-01 US US13/808,020 patent/US20140121258A1/en not_active Abandoned
- 2011-07-01 BR BR112013000065A patent/BR112013000065A2/pt not_active IP Right Cessation
- 2011-07-01 MX MX2013000170A patent/MX2013000170A/es active IP Right Grant
- 2011-07-01 SG SG2013000054A patent/SG186886A1/en unknown
-
2013
- 2013-01-02 CL CL2013000002A patent/CL2013000002A1/es unknown
- 2013-01-29 CO CO13016511A patent/CO6680625A2/es unknown
- 2013-05-20 US US13/898,254 patent/US20130253028A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2804194C (en) | 2019-03-05 |
| CL2013000002A1 (es) | 2013-05-31 |
| US20130253028A1 (en) | 2013-09-26 |
| AU2011272716A1 (en) | 2013-02-07 |
| US20120165382A1 (en) | 2012-06-28 |
| AR082073A1 (es) | 2012-11-07 |
| CN103038219A (zh) | 2013-04-10 |
| JP2013535424A (ja) | 2013-09-12 |
| CN103038219B (zh) | 2016-08-24 |
| AU2011272716B2 (en) | 2016-05-19 |
| JP5922116B2 (ja) | 2016-05-24 |
| US8492424B2 (en) | 2013-07-23 |
| CA2804194A1 (en) | 2012-01-05 |
| KR20130141434A (ko) | 2013-12-26 |
| RU2013102967A (ru) | 2014-08-10 |
| US20140121258A1 (en) | 2014-05-01 |
| MX2013000170A (es) | 2013-05-28 |
| WO2012003414A1 (en) | 2012-01-05 |
| SG186886A1 (en) | 2013-02-28 |
| ES2625355T3 (es) | 2017-07-19 |
| CO6680625A2 (es) | 2013-05-31 |
| EP2588459A1 (en) | 2013-05-08 |
| BR112013000065A2 (pt) | 2019-09-24 |
| TW201206891A (en) | 2012-02-16 |
| EP2588459B1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500121A1 (en) | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | |
| WO2013096496A3 (en) | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | |
| MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
| CR10771A (es) | Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f] indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide | |
| NZ592497A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| TW200736248A (en) | Compounds for the treatment of inflammatory disorders | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| MY152281A (en) | 4-pyrimidinesulfamide derivative | |
| PE20120911A1 (es) | Derivados de prolina como inhibidores de catepsina | |
| UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
| JO3387B1 (ar) | مشتقات بيتولين | |
| NZ594641A (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| AU2009310099A8 (en) | Agricultural compositions | |
| EA201391268A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ 2-ЭТОКСИ-1-((2'-((ГИДРОКСИАМИНО)ИМИНОМЕТИЛ)ДИФЕНИЛ-4-ИЛ)МЕТИЛ)-1H-БЕНЗО[d]ИМИДАЗОЛ-7-КАРБОНОВОЙ КИСЛОТЫ И ЕЕ СЛОЖНЫХ ЭФИРОВ | |
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| DK2285765T3 (da) | Fremgangsmåde til fremstilling af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre | |
| NZ600017A (en) | 5-hydroxypyrimidine-4-carboxamide derivative | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
| MX2013002031A (es) | Compuestos que actuan en multiples receptores de prostaglandina que proporcionan una respuesta antiinflamatoria general. | |
| PT2462098E (pt) | Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico | |
| MX2014004688A (es) | Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos. | |
| EA201200498A1 (ru) | Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| WO2010036638A3 (en) | Compounds for the treatment of inflammatory disorders |